Wyeth Pharmaceuticals initiates Phase II and pays Ablynx another milestone in the TNF-alpha Nanobody collaboration

02-Oct-2009 - Belgium

Ablynx announced that it has reached a second milestone under the terms of its collaboration with Wyeth Pharmaceuticals, a division of Wyeth. A milestone payment of $4 million has been triggered by the initiation by Wyeth of a first Phase II multiple dose study in patients with rheumatoid arthritis (RA) for a Nanobody® targeting tumour necrosis factor alpha (TNF-alpha).

Wyeth entered into a Phase I study in healthy volunteers in December 2008 in the USA and Japan. Based on a successful conclusion of that study, where the Nanobody® was safe and well tolerated, Wyeth has today initiated a multiple dose Phase II study in RA patients. Ablynx entered into an exclusive research collaboration and license agreement with Wyeth Pharmaceuticals in November 2006, a deal potentially worth $212.5 million for the successful development and commercialisation of multiple products. In addition, Ablynx is eligible to receive royalties on product sales. Wyeth has exclusive rights to develop and commercialise anti-TNF-alpha Nanobodies® developed under the collaboration. TNF-alpha is a key drug target in combating inflammation related disorders such as rheumatoid arthritis, Crohn's disease, psoriatic arthritis and ankylosing spondylitis.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...